<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320878</url>
  </required_header>
  <id_info>
    <org_study_id>SJTUMS-10-16</org_study_id>
    <nct_id>NCT01320878</nct_id>
  </id_info>
  <brief_title>Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease</brief_title>
  <official_title>A Randomized Controlled Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to assess the efficacy and appropriate dose of iloprost for
      inhalation in the treatment of postoperative pulmonary hypertension in children with
      congenital heart defects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary hypertension is a serious postoperative complication in children with congenital
      heart defects, which has a high incidence and mortality. Iloprost is a prostacyclin analogue.
      When applied by inhalation, it selectively dilates pulmonary vessels, without side affecting
      the systemic circulation. No randomized controlled trials (RCT) of iloprost have previously
      been performed in this indication. The investigators study is the first RCT of iloprost for
      inhalation after surgery of children's congenital heart diseases to be performed in this
      field.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause pulmonary artery pressure</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>central venous pressure</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac index</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary vascular resistance</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>iloprost low dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iloprost high dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>distilled water 2 ml per session</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iloprost nebuliser solution</intervention_name>
    <description>iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days</description>
    <arm_group_label>iloprost low dose group</arm_group_label>
    <other_name>Ventavis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iloprost nebuliser solution</intervention_name>
    <description>iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days</description>
    <arm_group_label>iloprost high dose group</arm_group_label>
    <other_name>Ventavis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>distilled water</intervention_name>
    <description>distilled water 2 ml per session</description>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>Treeful</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Before corrective procedure for CHD, two of bellow ten criteria should be met:

          -  Decreased respiratory infection &amp; decreased exercise tolerance

          -  Pulse SaO2 &lt; 93% in left-right shunt CHD case (in room air)

          -  EKG: right ventricular hypertrophy, right atrial dilatation

          -  Chest X-ray: enhanced vascular signs in trans-hilar, loss of blood vessel in bilateral
             lung fields, pulmonary arterial trunk dilatation, right ventricular enlargement

          -  Cardiac echocardiography: fast tricuspid or pulmonary valve regurgitant velocity,
             ventricular and aortic level bidirectional shunt, or even right-to-left shunt

          -  Underfilling of pulmonary capillary, 'pruning' of the peripheral blood vessels

          -  Pp/Ps &gt; 0.75

          -  Qp/Qs &lt;1.5

          -  PVR &gt; 9WU/m2

          -  Rp/Rs &gt; 0.5

        Exclusion Criteria:

          -  a body weight of &lt; 2 kg,

          -  prematurity (birth 36 weeks postconceptual age)

          -  renal dysfunction (creatinine &gt;= 1.5 mg/dL 48 hours before surgery)

          -  PLT &lt; 50,000*109/L and obvious bleeding

          -  LCOS or hypotension on arrival to the intensive care unit

        After corrective procedure for CHD:

          -  deficient anatomy associated with remained intracardiac shunts and severe
             artrio-ventricular regurgitation

          -  severe arrhythmia led to low cardiac output
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuo-ming Xu, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cardiac intensive Care Unit,Department of Thoracic and Cardiovascular Sugery,Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac intensive Care Unit,Department of Thoracic and Cardiovascular Sugery,Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. Cardiology. 2010;116(1):10-7. doi: 10.1159/000313864. Epub 2010 Apr 24.</citation>
    <PMID>20424447</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xu Zhuoming</investigator_full_name>
    <investigator_title>Director of Cardiac intensive Care Unit,Department of Thoracic and Cardiovascular Sugery,Shanghai Children's Medical Center.</investigator_title>
  </responsible_party>
  <keyword>pulmonary hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

